Yasin Akbari is an associate in the firm's Business Law Department and a member of its Technology and Life Sciences groups. Her practice covers a diverse range of complex transactions, including mergers and acquisitions, strategic investments and royalty-based financings, and securities offerings. She also counsels public and private companies on ongoing corporate matters, including SEC compliance and corporate governance.

Ms. Akbari is a member of the Boston Bar Association and the Women’s Bar Association. She joined Goodwin in 2015.

Areas of Practice
Domaines D’Expertise





Ms. Akbari’s recent client representations include, among others:

Mergers and Acquisitions

  • Corvidia Therapeutics in its sale to Novo Nordisk for $725 million upfront and up to $2.1 billion in total
  • ANA Therapeutics in its sale to NeuroBo Pharmaceuticals
  • Spark Therapeutics in its $4.8 billion sale to Roche
  • Twilio in its $3 billion acquisition of SendGrid
  • Keryx Biopharmaceuticals in its $1 billion merger with Akebia Therapeutics

Strategic Investments & Royalty-Based Financings

  • Alnylam Pharmaceuticals in its strategic financing collaboration with Blackstone Life Sciences, valued at $2 billion
  • Royalty Pharma in multiple transactions, including (i) its $2.025 billion strategic financing partnership with MorphoSys, (ii) its $827 million acquisition of Ligand Pharmaceuticals’ royalties on sales of Promacta, (iii) its purchase of worldwide royalties on sales of tazemetostat from Eisai and Epizyme and concurrent $100 million equity investment in Epizyme, (iv) its $320 million acquisition of Ultragenyx’s royalties on European sales of Crysvita; (v) its $100 million purchase of a synthetic royalty from, and equity investments of up $250 million in, Biohaven; (vi) its $94 million acquisition of MGH’s royalties on sales of Entyvio; (vii) its $220 million acquisition of a partial interest in AiCuris’ royalties on Prevymis; and (viii) its $255 million acquisition of Agios’ royalties on IDHIFA
  • Nektar Therapeutics in (i) its $150 million capped sale of royalties on Movantik, Adynovate and Rebinyn to Healthcare Royalty Partners and (ii) its $150 million financing and co-development collaboration with SFJ Pharmaceuticals to support the clinical development of bempegaldesleukin (BEMPEG)
  • RTW Investments in its strategic financing and licensing collaboration with Cytokinetics, valued at $200 million upfront
  • R-Bridge Healthcare Investment Advisory, Ltd. in its $60 million royalty- and revenue interest-backed loan to Paratek Pharmaceuticals
  • Cornerstone OnDemand in its $300 million strategic investment led by Silver Lake
  • Chiasma in its $75 million revenue interest financing with Healthcare Royalty Partners

Public Offerings

  • Cabaletta Bio in its $75 million initial public offering
  • TCR2 Therapeutics in its $75 million initial public offering
  • COMPASS Pathways in its $144 million April 2021 public offering
  • bluebird bio in its December 2016, December 2017, June 2017, July 2018 and May 2020 public offerings, raising over $2.5 billion
  • Blueprint Medicines in its December 2016, December 2017, April 2019 and January 2020 public offerings, raising over $1 billion
  • Revolution Healthcare Acquisition Corp., a SPAC formed by General Catalyst and ARCH Venture Partners, in its $500 million initial public offering
  • Consonance-HFW Acquisition Corp., a SPAC formed by Consonance Capital Management, in its $80 million initial public offering


While attending law school, Ms. Akbari served as a note editor for the International and Comparative Law Review and chaired the Women's Law Center.

In The News









J.D., 2015
Boston College Law School
(cum laude)
M.A., 2011
Yale University
B.A., 2010
Johns Hopkins University



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique